Tuesday, 21 August 2012

A prospective, open-label, single-arm study to evaluate efficacy, safety and acceptability of pericoital oral contraception with levonorgestrel

A prospective, open-label, single-arm study to evaluate efficacy, safety and acceptability of pericoital oral contraception with levonorgestrel

To assess the efficacy, safety and acceptability of pericoital use of oral levonorgestrel over 6.5 months in women who have infrequent sex. Healthy women who expected to have sex 1–4 days per month and who agreed to rely solely on the experimental contraceptive for 6.5 months were recruited at three sites in Brazil and the United States. We instructed each participant to take one tablet containing levonorgestrel 0.75 mg (HRA Pharma, Paris, France) within 24 hours before or after each sex act. Urine pregnancy testing was conducted at each of three scheduled follow-up visits (2.5, 4.5 and 6.5 months) and at home between scheduled visits. (Source: Contraception) read more..

No comments:

Post a comment